GeoVax Labs, Inc.

Listed Company

GOVXCIK 0000832489NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-21.46M

Total Assets

$6.34M

Equity

$3.83M

Shares Out

2.89M

Op. Cash Flow

$-21.47M

Business

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines and immunotherapies using proprietary MVA‑VLP and related platforms. Its main products include GEO‑CM04S1, a multi‑antigen COVID‑19 vaccine, Gedeptin®, a gene‑directed oncolytic therapy for solid tumors, GEO‑MVA for Mpox/smallpox, and multiple preclinical vaccine candidates. The company organizes around clinical development and preclinical research programs, platform technology and intellectual property licensing, and outsourced manufacturing partnerships. GeoVax pursues U.S. and international regulatory pathways and conducts clinical trials in collaboration with government agencies and third‑party contract manufacturers.

Summary from filing dated 2025-03-27

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenue from government contract	2	4	0	81,526	385,501
Research and development	18	24	21	9	16
General and administrative	6	5	6	5	4
Total operating expenses	24	29	27	14	19
Loss from operations	−22	−25	−27	−14	−19
Interest income	174,276	173,359	776,177	7,439	4,736
Interest expense	0	21,375	0	—	—
Total other income (expense)	174,276	151,984	776,177	7,439	175,506
Net loss	−21	−25	−26	−14	−19
Net loss per common share (in dollars per share)	−22.4	−120.46	−14.29	−12.39	−3.04
Weighted average shares outstanding (in shares)	958,443	207,482	2	1	6

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	3	6	6	28	11
Government contract receivable	0	659,409	0	—	—
Prepaid expenses and other current assets	2	2	1	1	156,240
Total current assets	5	8	8	29	12
Property and equipment, net	108,830	149,974	209,689	234,912	156,938
Operating lease right-of-use assets	831,440	0	—	—	—
Other assets	86,947	71,010	1	2	11,010
Total assets	6	8	9	31	12
Accounts payable	790,750	2	3	2	2
Accrued expenses	882,816	1	716,931	3	3
Operating lease liability, current portion	263,135	0	—	—	—
Total current liabilities	2	3	4	5	5
Operating lease liability, net of current portion	580,035	0	—	—	—
Total liabilities	3	3	—	5	7
Commitments and Contingencies	—	—	—	—	—
Common stock, $.001 par value: Authorized shares - 150,000,000 Issued and outstanding shares 1,732,147 and 421,475 at December 31, 2025 and 2024, respectively	1,732	421	1,977	1,756	6,382
Additional paid-in capital	155	134	110	105	69
Accumulated deficit	−151	−129	−104	−78	−64
Total stockholders equity	4	5	6	27	4
Total liabilities and stockholders equity	6	8	9	31	12

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation expense	68,756	95,368	74,169	56,284	38,521
Stock-based compensation expense	1	528,644	1	902,074	369,987
Government contract receivable	659,409	−659,409	0	49,006	133,657
Prepaid expenses and other current assets	−414,544	−352,047	−114,488	−1	−16,270
Other assets	−27,623	−1	986,498	−2	0
Accounts payable and accrued expenses	−1	−412,549	−1	−3	7
Total adjustments	−9,198	316,785	793,123	−5	7
Net cash used in operating activities	−21	−25	−25	−19	−11
Purchase of equipment	−27,612	−20,653	−48,946	−134,258	−47,718
Net cash used in investing activities	−27,612	−20,653	−48,946	−134,258	−47,718
Net proceeds from issuance of notes payable related parties	0	135,000	0	—	0
Repayment of notes payable related parties	0	−150,000	0	0	−27,864
Net proceeds from sale of common stock and warrants	19	21	0	28	9
Net proceeds from warrant exercises	156,209	2	4	8	3
Net cash provided by financing activities	19	24	4	35	13
Net increase (decrease) in cash and cash equivalents	−2	−945,648	−21	16	2

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro